Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
story of the week
Published in Oncology

Journal Scan / Research · July 26, 2017

Adjuvant Tamoxifen and Exemestane in Women With Postmenopausal Early Breast Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Adjuvant Tamoxifen and Exemestane in Women With Postmenopausal Early Breast Cancer (TEAM): 10-Year Follow-Up of a Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2017 Jul 18;[EPub Ahead of Print], MGM Derks, EJ Blok, C Seynaeve, JWR Nortier, EM Kranenbarg, GJ Liefers, H Putter, JR Kroep, D Rea, A Hasenburg, C Markopoulos, R Paridaens, JBE Smeets, LY Dirix, CJH van de Velde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading